Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy
Phase 3
Completed
NCT01282073
| Condition | Glomerulonephritis, Membranous |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | Kyungpook National University Hospital |
|---|
| Status | Completed |
|---|
| Enrollment | 43 participants |
|---|
| Interventions | Mycophenolate mofetil, low dose steroid, Cyclosporin, low dose steroid |
|---|
| Start date | Mar, 2011 |
|---|
| Completion date | May, 2016 |
|---|
| Results posted | Aug 27, 2025 |
|---|
Summary
Cyclosporin decreases proteinuria and improve renal function in patients with idiopathic membranous nephropathy, but has a risk of side effects such as nephrotoxicity. The investigators plan to the study to evaluate whether mycophenolate mofetil (MMF) could be a reasonable alternative with fewer side effect.
Percentage of Complete Remission
at 48 week after treatment · Participants
| Mycophenolate Mofetil, Low Dose Steroid | 4 Participants |
|---|
| Cyclosporin, Low Dose Steroid | 3 Participants |
|---|
Percentage of Partial Remission
at 48 week after treatment · Participants
| Mycophenolate Mofetil, Low Dose Steroid | 12 Participants |
|---|
| Cyclosporin, Low Dose Steroid | 9 Participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.